OKYO Pharma (OKYO) Notes Payables (2022 - 2025)

OKYO Pharma (OKYO) has reported Notes Payables for 4 consecutive years, with $233451.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Notes Payables fell 47.61% year-over-year to $233451.0 in Q3 2025; TTM through Sep 2025 was $233451.0, a 47.61% decrease from a year earlier, with the FY2025 full-year figure at $859325.0, up 139.56% from the prior year.
• Notes Payables was $233451.0 for Q3 2025 at OKYO Pharma, down from $859325.0 in the prior quarter.
• Over five years, Notes Payables peaked at $47.0 billion in Q1 2022 and troughed at $233451.0 in Q3 2025.
• A 4-year average of $6.7 billion and a median of $518546.0 in 2023 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables tumbled 100.0% in 2023 and soared 139.56% in 2025, its largest moves.
• Over 4 years, Notes Payables stood at $47.0 billion in 2022, then slumped by 100.0% to $518546.0 in 2023, then declined by 14.06% to $445634.0 in 2024, then slumped by 47.61% to $233451.0 in 2025.
• The last three Notes Payables figures came in at $233451.0 (Q3 2025), $859325.0 (Q1 2025), and $445634.0 (Q3 2024), per Business Quant data.